We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is This the Right Time to Hold MYGN Stock in Your Portfolio?
Read MoreHide Full Article
Key Takeaways
MYGN is launching new tests and upgrades across cancer, prenatal and precision medicine.
MYGN grew Cancer Care Continuum volumes 13% in Q1 2026, backed by hereditary cancer demand.
MYGN faces GeneSight reimbursement risk, plus inflation and tariff-related cost pressures.
Myriad Genetics, Inc. (MYGN - Free Report) is well-placed for growth in the coming quarters due to its steady rollout of new testing panels and product enhancements. The company is also progressing in its Cancer Care Continuum strategy, supported by rising demand in hereditary cancer and a 2026 launch calendar. Solid financial health further adds to its appeal. However, coverage and reimbursement changes for GeneSight remain a risk to Myriad Genetics' revenue growth. Macroeconomic headwinds and input cost pressures are other challenges.
Over the past year, this Zacks Rank #3 (Hold) company’s shares have risen 21.2% compared with the industry’s 20.4% growth and the S&P 500’s gain of 23.6%.
The renowned genetic testing and precision medicine company has a market capitalization of $553.5 million. The company’s earnings yield of 0.1% remains well ahead of the industry’s -14.4% yield. MYGN’s earnings surpassed estimates in three of the trailing four quarters and missed on one occasion, delivering an average surprise of 237.5%.
Tailwinds for MYGN Stock
Product Launches and Upgrades: Myriad Genetics continues to refresh its menu with new panels, regulatory progress and clinical data that can improve utility and reduce provider friction. After expanding the MyRisk panel to 63 genes across more than 11 cancer types, the company launched additional disease-specific panels in the first quarter of 2026. Myriad Genetics also enhanced the Foresight carrier screen by adding genes that make the offering compliant with American College of Medical Genetics and Genomics recommendations. Meanwhile, Prequel is positioned to provide results earlier in pregnancy.
In March, Myriad Genetics initiated a limited launch of Precise MRD for breast cancer patients and stated early customer feedback has been positive as community oncology workflows develop. In tumor profiling, the company received FDA approval for MyChoice CDx as a companion diagnostic for Zejula in advanced ovarian cancer, which can support broader guideline use. In prostate cancer, management expects to launch its AI-enhanced Prolaris test in June 2026.
Image Source: Zacks Investment Research
Renewed Strategic Priorities: Myriad Genetics continues to execute its Cancer Care Continuum strategy, using a dedicated hereditary cancer sales force and workflow programs to drive adoption. In the first quarter of 2026, overall Cancer Care Continuum volumes rose 13% year over year, with MyRisk growing 10% in the affected population and 16% in the unaffected population compared with the year-ago quarter. These trends supported 2% year-over-year revenue growth on stable total testing volumes.
Mental Health remains an important pillar, with GeneSight volumes up 7% year over year in the first quarter and ordering clinicians exceeding 39,000. Management also highlighted improved reimbursement trends and payer coverage in GeneSight, aided by biomarker legislation and revenue cycle optimization. While Prenatal volumes declined 12% year over year, Myriad Genetics is working on reactivating accounts, expanding access and preparing for the FirstGene launch to support a return to growth in the second half of 2026.
Sound Solvency With Slight Leverage: Myriad Genetics exited the first quarter of 2026 with $124.4 million of cash and cash equivalents, down from $149.6 million as of Dec. 31, 2025. This reflects typical first-quarter cash burn and increased commercial investment. Long-term debt was $120.3 million at quarter-end, broadly consistent with year-end 2025. Management noted access to $199 million in capital, which provides the flexibility to fund planned launches while maintaining financial discipline.
What Concerns MYGN Stock?
GeneSight Coverage End Risks Revenues: Coverage decisions remain a key swing factor for Myriad Genetics’ Mental Health franchise. While GeneSight test volume grew 7% year over year in the first quarter of 2026 and revenues increased 24% to $38.3 million on improved reimbursement trends, the business remains exposed to payor policy changes that can alter access, pricing and cash flow. The broader company revenue increase of 2% year over year still reflects a mix of offsets across categories. Any renewed coverage tightening could limit operating leverage as Myriad Genetics invests in launches.
Macroeconomic Pressures: Myriad Genetics operates across multiple reimbursement regimes and faces ongoing cost exposure in labor, laboratory supplies and commercial execution. Management expects gross margins to fluctuate quarter to quarter in 2026 based on product mix and pricing trends, even as adjusted gross margin guidance remains 68% to 69%. Tariff-related input costs and inflation can be difficult to pass through in diagnostic testing, and a slower spending environment at provider offices could extend the time needed to rebuild Prenatal Health volumes after recent ordering disruption and account reactivation efforts.
MYGN Stock Estimate Trend
In the past 30 days, the Zacks Consensus Estimate for the company’s 2026 earnings per share (EPS) has remained constant at 1 cent.
The Zacks Consensus Estimate for 2026 revenues is pegged at $859.2 million, suggesting a 4.2% increase from the year-ago reported number.
Top MedTech Stocks
Some better-ranked stocks in the broader medical space are Phibro Animal Health (PAHC - Free Report) , Align Technology (ALGN - Free Report) and Integra LifeSciences (IART - Free Report) .
Phibro Animal Health has an earnings yield of 10.1% compared with the industry’s 3% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 16.3%. PAHC shares have rallied 8.1% against the industry’s 27.9% decline over the past year.
Align Technology, carrying a Zacks Rank #2, has an estimated long-term earnings growth rate of 10.3% compared with the industry’s 5.5% growth. Shares of the company have dipped 7.4% against the industry’s 11.7% growth. ALGN’s earnings outpaced estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 7.8%.
Integra LifeSciences, carrying a Zacks Rank #2, has an earnings yield of 13.7% against the industry’s negative 3% yield. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with the average surprise being 16.7%. IART shares have rallied 56.7% against the industry’s 5.3% decline over the past year.
View the Zacks #1 Rank List
Image: Bigstock
Is This the Right Time to Hold MYGN Stock in Your Portfolio?
Key Takeaways
Myriad Genetics, Inc. (MYGN - Free Report) is well-placed for growth in the coming quarters due to its steady rollout of new testing panels and product enhancements. The company is also progressing in its Cancer Care Continuum strategy, supported by rising demand in hereditary cancer and a 2026 launch calendar. Solid financial health further adds to its appeal. However, coverage and reimbursement changes for GeneSight remain a risk to Myriad Genetics' revenue growth. Macroeconomic headwinds and input cost pressures are other challenges.
Over the past year, this Zacks Rank #3 (Hold) company’s shares have risen 21.2% compared with the industry’s 20.4% growth and the S&P 500’s gain of 23.6%.
The renowned genetic testing and precision medicine company has a market capitalization of $553.5 million. The company’s earnings yield of 0.1% remains well ahead of the industry’s -14.4% yield. MYGN’s earnings surpassed estimates in three of the trailing four quarters and missed on one occasion, delivering an average surprise of 237.5%.
Tailwinds for MYGN Stock
Product Launches and Upgrades: Myriad Genetics continues to refresh its menu with new panels, regulatory progress and clinical data that can improve utility and reduce provider friction. After expanding the MyRisk panel to 63 genes across more than 11 cancer types, the company launched additional disease-specific panels in the first quarter of 2026. Myriad Genetics also enhanced the Foresight carrier screen by adding genes that make the offering compliant with American College of Medical Genetics and Genomics recommendations. Meanwhile, Prequel is positioned to provide results earlier in pregnancy.
In March, Myriad Genetics initiated a limited launch of Precise MRD for breast cancer patients and stated early customer feedback has been positive as community oncology workflows develop. In tumor profiling, the company received FDA approval for MyChoice CDx as a companion diagnostic for Zejula in advanced ovarian cancer, which can support broader guideline use. In prostate cancer, management expects to launch its AI-enhanced Prolaris test in June 2026.
Image Source: Zacks Investment Research
Renewed Strategic Priorities: Myriad Genetics continues to execute its Cancer Care Continuum strategy, using a dedicated hereditary cancer sales force and workflow programs to drive adoption. In the first quarter of 2026, overall Cancer Care Continuum volumes rose 13% year over year, with MyRisk growing 10% in the affected population and 16% in the unaffected population compared with the year-ago quarter. These trends supported 2% year-over-year revenue growth on stable total testing volumes.
Mental Health remains an important pillar, with GeneSight volumes up 7% year over year in the first quarter and ordering clinicians exceeding 39,000. Management also highlighted improved reimbursement trends and payer coverage in GeneSight, aided by biomarker legislation and revenue cycle optimization. While Prenatal volumes declined 12% year over year, Myriad Genetics is working on reactivating accounts, expanding access and preparing for the FirstGene launch to support a return to growth in the second half of 2026.
Sound Solvency With Slight Leverage: Myriad Genetics exited the first quarter of 2026 with $124.4 million of cash and cash equivalents, down from $149.6 million as of Dec. 31, 2025. This reflects typical first-quarter cash burn and increased commercial investment. Long-term debt was $120.3 million at quarter-end, broadly consistent with year-end 2025. Management noted access to $199 million in capital, which provides the flexibility to fund planned launches while maintaining financial discipline.
What Concerns MYGN Stock?
GeneSight Coverage End Risks Revenues: Coverage decisions remain a key swing factor for Myriad Genetics’ Mental Health franchise. While GeneSight test volume grew 7% year over year in the first quarter of 2026 and revenues increased 24% to $38.3 million on improved reimbursement trends, the business remains exposed to payor policy changes that can alter access, pricing and cash flow. The broader company revenue increase of 2% year over year still reflects a mix of offsets across categories. Any renewed coverage tightening could limit operating leverage as Myriad Genetics invests in launches.
Macroeconomic Pressures: Myriad Genetics operates across multiple reimbursement regimes and faces ongoing cost exposure in labor, laboratory supplies and commercial execution. Management expects gross margins to fluctuate quarter to quarter in 2026 based on product mix and pricing trends, even as adjusted gross margin guidance remains 68% to 69%. Tariff-related input costs and inflation can be difficult to pass through in diagnostic testing, and a slower spending environment at provider offices could extend the time needed to rebuild Prenatal Health volumes after recent ordering disruption and account reactivation efforts.
MYGN Stock Estimate Trend
In the past 30 days, the Zacks Consensus Estimate for the company’s 2026 earnings per share (EPS) has remained constant at 1 cent.
The Zacks Consensus Estimate for 2026 revenues is pegged at $859.2 million, suggesting a 4.2% increase from the year-ago reported number.
Top MedTech Stocks
Some better-ranked stocks in the broader medical space are Phibro Animal Health (PAHC - Free Report) , Align Technology (ALGN - Free Report) and Integra LifeSciences (IART - Free Report) .
Phibro Animal Health has an earnings yield of 10.1% compared with the industry’s 3% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 16.3%. PAHC shares have rallied 8.1% against the industry’s 27.9% decline over the past year.
PAHC carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Align Technology, carrying a Zacks Rank #2, has an estimated long-term earnings growth rate of 10.3% compared with the industry’s 5.5% growth. Shares of the company have dipped 7.4% against the industry’s 11.7% growth. ALGN’s earnings outpaced estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 7.8%.
Integra LifeSciences, carrying a Zacks Rank #2, has an earnings yield of 13.7% against the industry’s negative 3% yield. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with the average surprise being 16.7%. IART shares have rallied 56.7% against the industry’s 5.3% decline over the past year.